Given all of the closures, what is EZPW's sustainable forward free cash flow, and EBITDA? I'm interested in the true free cash flow, not operating cash flows.
Obviously you have no time in the markets. This selloff is nothing, and it is healthy for the continued bull market.
Stock prices are being driven by low interest rates and the lack of good investment alternatives. The bankruptcy of a two-bit country like Greece is not likely to affect US markets for more than three months, if that.
What is the range of possible 2P reserves we could get out ot the Israeli exploration? Has company hinted at extraction costs / netbacks, and do those include the cost to discover the oil?
I didn't say buy a Greek stock today. I asked do you know of any that get most of their earnings from USD or Euros, that would be undervalued if they crashed after a Greek exit. *after* is the key word.
Does anyone know what the borrow cost is to short GREK? Most of these ETFs impose huge financing costs to any broker that wants to go short, so I will be surprised if this is cheap.
John, what are some Greek stocks that you think will do well in an environment with a highly deflated Drachma? I've been looking for Greek stocks that get most of their income in USD or Euros, that will not be deflated in earnings severely by a Greek exit. Very slim pickings here I think, but I'm sure there must be a handful to watch?
Is there any reason that Venaxis doesn't pursue a marketing partner for the US market, to help absorb costs for any new retest requirements from the FDA? Is Venaxis saying they want to market the drug themselves, or did they just want to wait until after FDA approval to get the marketing partner because it would improve the size of up front payments and lead to better overall deal?
Does anyone know of a good writeup showing market potential for next 18 months in Europe? Unlikely Spain alone is going to fund a $20M/year operating loss any time soon.
I found a study that claims false negative rate for ultrasound alone of 12%. Can someone summarize a broader set of data? I tried to post the link, but Yahoo not only doesn't let me do that, but simply makes 20 minutes of my time typing in a longer message disappear. (Amazing that nearly 20 years after starting this web site, Yahoo still can't get anything here to work well.)
Venaxis claims a 99.3% success rate for ultrasound and APPY together, which implies a 0.7% false negative rate. The company's presentation on the 24th was simply awful. The CEO failed to sell the value of the new suggested use. Potential value propositions:
1) Ultrasound and APPY together are vastly more accurate than ultrasound alone.
2) APPY may speed up the diagnostic pathway, as a quicker positive result will allow the facility to fast-track the patient.
What is the current diagnostic pathway for a person that ultrasound gives a false negative to? That person is sent home?
MEET is trying to tell us that they are enjoying healthy grow of users and revenue in their mobile applications. Why then is Meetme as a search trend on Google flat?
The fact that there is no growth confirmed outside of the company's disclosures suggest that maybe the reported growth is just a gimmick, not a sustainable trend.
But it is important to understand WHY it is going nowhere.
The fundamental results are interesting, and there might be an argument for undervaluation for a growing social media stock.
The problem is the management is raping the shareholders by grabbing huge parts of the company every year, on top of enormous salaries. All they do is create an oversupply of people who want to sell the stock, and ultimately the sellers overwhelm the modest success in fundamentals they are reporting.
Unless I completely misunderstand the stock-based compensation issue (and maybe I do), that level of compensation - combined with an explicit attempt to hide that compensation by taking it out of their perverse definition of EBITDA - constitutes an completely unethical move. That level of theft from shareholders should not even be allowed in a public market.
Am I reading the 2014 annual report correctly that MEET has almost $4M in annual stock based compensation expenses? The footnote to their EBITDA calculation in a recent press release seems to suggest they are excluding that number from their non-GAAP "Adjusted EBITDA" calculation?
$4M of stock based compensation per year for a company with such a small market cap is obscene.
And the company wonders why their stock makes no progress and always sells off? They are setting up the conditions for their constant underperformance.
I see two entities that are major shareholders in MEET that have names suggesting a Mexican owner:
MEXICANS & AMERICANS TRADING TOGETHER, INC
BLAST FURNACES OF MEXICO
Are these related parties? What's the history that had these entities owning so much of MEET?
Both of these entities have been major sellers of the stock and probably account for much of the downward price momentum.
Has anyone noticed that Cellcom's stock mirrors exactly the stocks of competitors like Partner Communications? It's almost uncanny, but if you overlay the two stocks it is like a computer is sitting there balancing trades to keep them in an exact proportion to each other. Anyone have an explanation of the reason for this?
It cannot be the case that both businesses have exactly parallel financial metrics?
It's particularly surprising given that Cellcom wants to raise money at this point in the cycle. You would think that would cause an additional sell off in the stock beyond what is happening in Partner?
It looks like the Ruble has really collapsed, probably reflecting the collapse in oil pricing. Is the currency what keeps Gazprom priced so low? Gazprom is being paid by European customers for what percentage of its revenue? What is the currency for those transactions? How much of Gazprom's cash is being kept in currencies other than Rubles?
If Russia uses up all of its foreign currency reserves in the next three years, then defaults (again), where does this leave Gazprom?
The market is obviously trying to price in some specific risks here, and I want to understand those.
Does anyone have a good symbol to track Ruble against any major currency?